Corporate calendar for Editas Medicine, Inc. (EDIT): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | ||
| 2026-09-14 | $563M | |
| 2026-09-14 | ||
| 2026-09-14 | $159M | |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 |
Price
| Price | $2.71 |
| Market Cap | $416M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALLO · AVIR · CABA · CAPR · IMMP · KYTX · LYEL
Explore sector: Healthcare · Biotechnology
More sections of EDIT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks